<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054387</url>
  </required_header>
  <id_info>
    <org_study_id>LPS16583</org_study_id>
    <secondary_id>U1111-1255-4881</secondary_id>
    <nct_id>NCT05054387</nct_id>
  </id_info>
  <brief_title>China Post-marketing Surveillance (PMS) Study of Fabrazyme®</brief_title>
  <official_title>A Phase 4, Open Label, Safety and Efficacy Study of Fabrazyme® (Agalsidase Beta) as Enzyme Replacement Therapy in Chinese Participants With Fabry Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genzyme, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 54-week Phase 4, open label, single arm study to evaluate the safety and the&#xD;
      efficacy of Fabrazyme (agalsidase beta) as enzyme replacement therapy (ERT) in Chinese&#xD;
      participants with Fabry Disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study participation for each patient will be total of 54 weeks which will include 4 weeks of&#xD;
      screening, 48 weeks of treatment period and 2 weeks of post study treatment observation&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 13, 2021</start_date>
  <completion_date type="Anticipated">October 11, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (AEs)</measure>
    <time_frame>Baseline to week 50</time_frame>
    <description>Including TEAE, SAEs, and adverse events of special interest (AESIs) including infusion associated reactions (IARs) and change of clinical laboratory, vital signs and ECG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The absolute changes of plasma globotriaosylsphingosine (lyso-GL3)</measure>
    <time_frame>from baseline to Week 6, Week 12, Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent changes of plasma lyso-GL3</measure>
    <time_frame>from baseline to Week 6, Week 12, Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute changes of plasma globotriaosylceramide (GL3)</measure>
    <time_frame>from baseline to Week 6, Week 12, Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percent changes of plasma GL3</measure>
    <time_frame>from baseline to Week 6, Week 12, Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of participants with abnormal plasma GL3 values per central lab reference range</measure>
    <time_frame>at Week 6, Week 12, Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of participants with abnormal plasma GL3 values per central lab reference range</measure>
    <time_frame>at Week 6, Week 12, Week 24 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change of Fabry disease symptoms</measure>
    <time_frame>from baseline to Week 24 and Week 48</time_frame>
    <description>The change of Fabry disease symptoms assessment (improved, worsen or same): angiokeratoma, sweating, chronic abdominal pain, level of activity, exercise tolerance and heat tolerance, headache, tinnitus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change of estimated glomerular filtration rate (eGFR) by chronic kidney disease epidemiology collaboration (CKD-EPI) for adult (≥18 years)</measure>
    <time_frame>from baseline to Week 12, Week 24, Week 36 and Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The absolute change of estimated glomerular filtration rate (eGFR) by Schwartz for children (8 ≤age &lt;18 years)</measure>
    <time_frame>from baseline to Week 12, Week 24, Week 36 and Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">22</enrollment>
  <condition>Fabry's Disease</condition>
  <arm_group>
    <arm_group_label>Agalsidase beta</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Agalsidase beta treatment at approved dose and regimen, administered once every 2 weeks as an IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Agalsidase beta</intervention_name>
    <description>Powder for concentration into a solution Intravenous (IV) infusion</description>
    <arm_group_label>Agalsidase beta</arm_group_label>
    <other_name>GZ419828 Fabrazyme</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 8 years of age or older, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Participants naive to agalsidase beta and agalsidase alpha&#xD;
&#xD;
          -  Chinese participants diagnosed with Fabry disease and with documented plasma or&#xD;
             leukocyte αGAL activity deficient below laboratory's reference range, and/or&#xD;
             documented diagnosis by genotyping&#xD;
&#xD;
          -  Participants must have one or more symptoms and signs consistent with manifestations&#xD;
             of Fabry disease (not limited to neuropathic pain, chronic kidney disease,&#xD;
             hypertrophic cardiomyopathy, cardiac rhythm disturbances, cerebrovascular involvement,&#xD;
             cornea verticillata, angiokeratoma, gastrointestinal symptoms, hypo- or anhydrosis)&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding and use an acceptable contraceptive method&#xD;
&#xD;
          -  Participants and/or participant's legal representative capable of giving signed&#xD;
             informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The participant has undergone kidney transplantation.&#xD;
&#xD;
          -  The participant has a clinically significant organic disease (with the exception of&#xD;
             symptoms relating to Fabry disease) in the opinion of the Investigator, would preclude&#xD;
             participation in the trial.&#xD;
&#xD;
          -  Received an investigational drug, or device, other than Fabrazyme, within 30 days of&#xD;
             anticipated IMPs administration or 5 half-lives of the previous investigational drug,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  The patient has current evidence of kidney failure or renal insufficiency, as defined&#xD;
             by eGFR &lt;30 mL/min/1.73 m2.&#xD;
&#xD;
          -  Individuals who have life threatening hypersensitivity (anaphylactic reaction) to the&#xD;
             active substance or any of the excipients included.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :1560004</name>
      <address>
        <city>Shanghai</city>
        <zip>201102</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 29, 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fabry Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

